Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Programmed cell death ligand 1 (PD-L1) on tumor cells interacts with programmed cell death 1 (PD-1) on T cells, hindering anti-tumor immune responses and promoting immune evasion.
• Blocking the PD-1/PD-L1 pathway is a key immunotherapy strategy that has shown efficacy in various cancers.

Purpose of the Study:

• To review the structure and posttranslational modification mechanisms regulating PD-1/PD-L1.
• To provide an overview of clinical research combining PD-1/PD-L1 blocking antibodies with strategies targeting posttranslational modifications.
• To explore methods for overcoming limitations such as limited indications and drug resistance in current immunotherapies.

Main Methods:

• Literature review of foundational and clinical research on PD-1/PD-L1 interactions.
• Analysis of posttranslational modification pathways affecting PD-1/PD-L1 function.
• Synthesis of data on combination therapies involving PD-1/PD-L1 blockade.

Main Results:

• PD-1/PD-L1 pathway blockade is effective but faces challenges including resistance and limited applicability.
• Posttranslational modifications significantly regulate PD-1/PD-L1 activity and represent potential therapeutic targets.
• Combination strategies targeting PD-1/PD-L1 and its modifications show promise for broader patient benefit.

Conclusions:

• Understanding PD-1/PD-L1 posttranslational modifications is essential for enhancing cancer immunotherapy.
• Targeting these modifications alongside PD-1/PD-L1 blockade may overcome current treatment limitations.
• Further research and clinical trials are needed to optimize combination therapies for improved patient outcomes.